CPT® Code 82017

Official Description

Acylcarnitines; quantitative, each specimen

Common Language Description

The CPT® Code 82017 refers to a quantitative test for acylcarnitines, which are compounds involved in the metabolism of fatty acids. This blood test is specifically designed to measure the levels of acylcarnitines in the blood, providing critical information for diagnosing metabolic disorders. The qualitative counterpart, CPT® Code 82016, identifies the presence or absence of acylcarnitines and is commonly performed as part of newborn screening to detect conditions such as fatty acid beta-oxidation disorders and organic acidurias. While the qualitative test is routinely conducted on infants, the quantitative test can be performed at any age when symptoms indicative of these metabolic disorders are present. To conduct the test, a blood sample is collected through a venipuncture or capillary draw, which is a separately reportable procedure. The collected plasma or whole blood is then analyzed using low injection analysis-tandem mass spectrometry, a sophisticated technique that allows for precise measurement of acylcarnitine levels. The results of the quantitative test can indicate specific elevations in acylcarnitines, such as Elevated Isolated C4 Acylcarnitine, Elevated Isolated C5 Acylcarnitine, or elevations of C8, C6, and C10 Acylcarnitine. Each specimen obtained for this test must be reported using CPT® Code 82017, ensuring accurate tracking and billing for the laboratory services provided.

1. Indications

The quantitative acylcarnitines test (CPT® Code 82017) is indicated for the following conditions:

Follow-up to Positive Newborn Screening This test is often performed as a follow-up to a positive qualitative newborn screening test for acylcarnitines, which may indicate the presence of metabolic disorders.
Symptoms of Metabolic Disorders The test may be conducted at any age when symptoms suggestive of fatty acid beta-oxidation disorders or organic acidurias are present.

2. Procedure

The procedure for obtaining and analyzing acylcarnitines involves several key steps:

Step 1: Sample Collection A blood sample is obtained from the patient through a venipuncture or capillary draw. This step is crucial as it ensures that the specimen is suitable for testing. The method of collection must be reported separately, as it is a distinct procedure.
Step 2: Plasma Preparation Once the blood sample is collected, it is processed to separate the plasma or whole blood, which is necessary for the subsequent analysis. Proper handling and preparation of the sample are essential to maintain the integrity of the acylcarnitines for accurate measurement.
Step 3: Analytical Testing The prepared plasma is then subjected to low injection analysis-tandem mass spectrometry. This advanced analytical technique allows for the precise quantification of acylcarnitines in the blood, providing detailed information about the levels present.
Step 4: Reporting Results After the analysis is complete, the results are interpreted, and any elevations in specific acylcarnitines are documented. Each specimen analyzed is reported using CPT® Code 82017, ensuring accurate billing and tracking of the laboratory services rendered.

3. Post-Procedure

Post-procedure care for patients undergoing the acylcarnitines test typically involves monitoring for any immediate reactions to the blood draw, although significant complications are rare. Patients may resume normal activities following the procedure. The results of the quantitative test will be reviewed by the healthcare provider, who will discuss the findings with the patient and determine any necessary follow-up actions or treatments based on the levels of acylcarnitines detected. It is important for healthcare professionals to ensure that patients understand the implications of the test results and any further diagnostic steps that may be required.

Short Descr	ACYLCARNITINES QUANT
Medium Descr	ACYLCARNITINES QUANTIATIVE EACH SPECIMEN
Long Descr	Acylcarnitines; quantitative, each specimen
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
CLIA Waived (QW)	No
APC Status Indicator	Conditionally packaged laboratory tests
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	1
CCS Clinical Classification	233 - Laboratory - Chemistry and Hematology

90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.